slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,557
Current window 43,591-43,620
Pages 2,019
Rows per page 30
Component
43,591-43,620 of 60,557
10
The table highlights the clinical gap in patients with prior kinase inhibitor treatment, specifically those with G2032R mutations.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction1 hit
11
The table uses a green/white color coding to highlight positive attributes (Yes) versus negative ones (No).Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
17
The table highlights a heavily pretreated population, with 77% having received 3 or more prior lines of therapy and 71% having received 2 or more prior ROS1 TKIs.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
18
Data as of 13 Sep 22. N=35 patients.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
20
Clinical trial data table showing efficacy metrics for NVL-520 in NSCLC patients.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
21
The chart uses a waterfall plot to visualize clinical efficacy, a standard in oncology drug development.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
28
Includes detailed clinical trial design, cohort definitions, and study objectives.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
30
The slide uses a structured table to segment the patient population based on treatment history and specific genetic mutations.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
31
The table highlights NVL-655's superior profile in G1202R and GRLM/GRGA/GRLF activity compared to existing therapies.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
34
Clinical trial design slide detailing patient population, objectives, and cohort structure.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
36
Clinical trial baseline characteristics table.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
37
Data cut-off: 8 Aug 2023. Includes detailed footnotes regarding specific patient events.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
40
Data cut-off: 8 Aug 2023. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
41
The slide uses a split waterfall plot to compare two patient cohorts. It includes a detailed data table below the chart showing dose levels and prior treatment history.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
50
The slide uses a Gantt-chart style visualization to show the progress of three specific drug candidates (NVL-520, NVL-655, NVL-330) through clinical development phases.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
11
The slide uses a split-screen comparison between UK market ranking improvements and German volume growth metrics.Oatly | Results Presentation Deck | 39 slides · Oatly
Conference presentation Investor relations Beat · SatisfactionLoop · Quick Win Big Bet1 hit
24
The slide includes a footnote regarding non-IFRS measures and currency units.Oatly | Results Presentation Deck | 39 slides · Oatly
Conference presentation Investor relations Beat · VisualizationLoop · Why Now1 hit
26
The table uses a waterfall-style logic to bridge volume and price/mix to total revenue growth.Oatly | Results Presentation Deck | 39 slides · Oatly
Conference presentation Investor relations Beat · VisualizationLoop · Why Now1 hit
28
The table shows segment-level profitability with negative values in parentheses.Oatly | Results Presentation Deck | 39 slides · Oatly
Conference presentation Investor relations Beat · VisualizationLoop · Why Now1 hit
30
The slide uses a before-after comparison structure to communicate guidance updates.Oatly | Results Presentation Deck | 39 slides · Oatly
Conference presentation Investor relations Beat · VisualizationLoop · Why Now1 hit
35
Oatly | Results Presentation Deck | 39 slidesOatly | Results Presentation Deck | 39 slides · Oatly
Conference presentation Investor relations 1 hit
36
Includes footnotes explaining corporate costs, intersegment eliminations, restructuring costs, and legal settlements.Oatly | Results Presentation Deck | 39 slides · Oatly
Conference presentation Investor relations 1 hit
37
The slide provides a detailed breakdown of financial metrics across EMEA, Americas, Asia, Corporate, and Eliminations, reconciling non-IFRS measures to Loss before tax.Oatly | Results Presentation Deck | 39 slides · Oatly
Conference presentation Investor relations 1 hit
38
Includes footnotes explaining corporate allocations, intersegment eliminations, and specific transaction costs.Oatly | Results Presentation Deck | 39 slides · Oatly
Conference presentation Investor relations 1 hit
39
Oatly | Results Presentation Deck | 39 slidesOatly | Results Presentation Deck | 39 slides · Oatly
Conference presentation Investor relations 1 hit
21
The table provides a breakdown of non-GAAP adjustments for Q1, Q2, Q3, Q4, and full-year 2022.Orthofix | Investor Presentation Deck | 22 slides · Orthofix
Pitch deck Investor relations Beat · Financials1 hit
22
Includes a disclaimer regarding non-GAAP financial measures and merger-related adjustments.Orthofix | Investor Presentation Deck | 22 slides · Orthofix
Pitch deck Investor relations Beat · Financials1 hit
03
Values are in thousands.P3 Health Partners | Results Presentation Deck | 4 slides · P3 Health Partners
Conference presentation Investor relations 1 hit
04
P3 Health Partners | Results Presentation Deck | 4 slidesP3 Health Partners | Results Presentation Deck | 4 slides · P3 Health Partners
Conference presentation Investor relations 1 hit
08
The slide uses a matrix to demonstrate cross-platform monetization strategy for specific media assets.Paramount | Investor Presentation Deck | 27 slides · Paramount Global
Conference presentation Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit